{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:39:26Z","timestamp":1782837566063,"version":"3.54.5"},"reference-count":22,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Histopathology"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Liquid biopsy (LBx)\u2010based next\u2010generation sequencing (NGS) of circulating tumour DNA (ctDNA) can facilitate molecular profiling of haematopoietic neoplasms (HNs), particularly when tissue\u2010based NGS is infeasible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>We studied HN LBx samples tested with FoundationOne Liquid CDx, FoundationOne Liquid, or FoundationACT between July 2016 and March 2022. We identified 271 samples: 89 non\u2010Hodgkin lymphoma (NHL), 43 plasma\u2010cell neoplasm (PCN), 41 histiocytoses, 27 myelodysplastic syndrome (MDS), 25 diffuse large B\u2010cell lymphoma (DLBCL), 22 myeloproliferative neoplasm (MPN), 14 Hodgkin lymphoma (HL), and 10 acute myeloid leukaemia (AML). Among 73.4% with detectable pathogenic alterations, median maximum somatic allele frequency (MSAF) was 16.6%, with AML (36.2%), MDS (19.7%), and MPN (44.5%) having higher MSAFs than DLBCL (3.9%), NHL (8.4%), HL (1.5%), PCN (2.8%), and histiocytoses (1.8%) (<jats:italic>P<\/jats:italic>\u2009=\u20090.001). LBx detected characteristic alterations across HNs, including in <jats:italic>TP53<\/jats:italic>, <jats:italic>KRAS<\/jats:italic>, <jats:italic>MYD88<\/jats:italic>, and <jats:italic>BTK<\/jats:italic> in NHLs; <jats:italic>TP53<\/jats:italic>, <jats:italic>KRAS<\/jats:italic>, <jats:italic>NRAS<\/jats:italic>, and <jats:italic>BRAF<\/jats:italic> in PCNs; <jats:italic>IGH<\/jats:italic> in DLBCL; <jats:italic>TP53<\/jats:italic>, <jats:italic>ATM<\/jats:italic>, and <jats:italic>PDCD1LG2<\/jats:italic> in HL; <jats:italic>BRAF<\/jats:italic> and <jats:italic>MAP2K1<\/jats:italic> in histiocytoses; <jats:italic>TP53<\/jats:italic>, <jats:italic>SF3B1<\/jats:italic>, <jats:italic>DNMT3A<\/jats:italic>, <jats:italic>TET2<\/jats:italic>, and <jats:italic>ASXL1<\/jats:italic> in MDS; <jats:italic>JAK2<\/jats:italic> in MPNs; and <jats:italic>FLT3<\/jats:italic>, <jats:italic>IDH2<\/jats:italic>, and <jats:italic>NPM1<\/jats:italic> in AML. Among 24 samples, the positive percent agreement by LBx was 75.7% for variants present in paired buffy coat, marrow, or tissues. Also, 75.0% of pairs exhibited alterations only present on LBx. These were predominantly subclonal (clonal fraction of 3.8%), reflecting the analytical sensitivity of LBx.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These data demonstrate that LBx can detect relevant genomic alterations across HNs, including at low clonal fractions, suggesting a potential clinical utility for identifying residual or emerging therapy\u2010resistant clones that may be undetectable in site\u2010specific tissue biopsies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/his.15168","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:53:50Z","timestamp":1709247230000},"page":"1224-1237","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Liquid biopsy\u2010based circulating tumour (<scp>ct)DNA<\/scp> analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8059-8668","authenticated-orcid":false,"given":"Douglas A","family":"Mata","sequence":"first","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K","family":"Lee","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vignesh","family":"Shanmugam","sequence":"additional","affiliation":[{"name":"Department of Pathology Brigham and Women's Hospital and Harvard Medical School  Boston MA USA"},{"name":"Cancer Program Broad Institute of MIT and Harvard  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea B","family":"Marcus","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B","family":"Schrock","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik A","family":"Williams","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"},{"name":"Department of Pathology and Laboratory Medicine University of Miami Miller School of Medicine  Miami FL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren L","family":"Ritterhouse","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Hickman","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Janovitz","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh R","family":"Patel","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Morrisville NC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R","family":"Kroger","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Internal Medicine University of Texas Southwestern Medical Center  Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"},{"name":"Departments of Pathology, Urology, and Medicine (Oncology) State University of New York Upstate Medical University  Syracuse New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran M","family":"Mirza","sequence":"additional","affiliation":[{"name":"Department of Pathology Michigan Medicine  Ann Arbor MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey R","family":"Oxnard","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u2010Anne","family":"Vergilio","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A","family":"Elvin","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal K","family":"Benhamida","sequence":"additional","affiliation":[{"name":"Department of Pathology Memorial Sloan Kettering Cancer Center  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-7421","authenticated-orcid":false,"given":"Brennan","family":"Decker","sequence":"additional","affiliation":[{"name":"Foundation Medicine, Inc.  Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9513-245X","authenticated-orcid":false,"given":"Mina L","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pathology Yale New\u2010Haven Hospital, Yale School of Medicine  New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.02.006"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.131128"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.632910"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007094"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2018.05.004"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213457"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664649"},{"key":"e_1_2_11_12_1","volume-title":"Statistical guidance on reporting results from studies evaluating diagnostic tests\u2014guidance for industry and FDA staff [Internet]","author":"Center for Devices and Radiological Health","year":"2007"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.6286"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-022-00677-1"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8545"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635169"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70106-3"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0987"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2305"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008174"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0111-6"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030155"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112774"}],"container-title":["Histopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/his.15168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T10:26:07Z","timestamp":1713954367000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/his.15168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/his.15168"],"URL":"https:\/\/doi.org\/10.1111\/his.15168","archive":["Portico"],"relation":{},"ISSN":["0309-0167","1365-2559"],"issn-type":[{"value":"0309-0167","type":"print"},{"value":"1365-2559","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"2023-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}